Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953340 · ClinicalTrials.gov registry record · Phase 3
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
A Phase 3 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 237
- Enrollment target
NCT02953340 is a Phase 3 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 237 participants.
The verdict
NCT02953340, a Phase 3 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 237 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Pegfilgrastim
- DRUG SPI-2012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2017-05-10 |
| Est. Completion | 2019-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953340
The ClinicalTrials.gov registry entry for NCT02953340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02953340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953340 about?
NCT02953340 is a clinical study titled "SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide". The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).
What is the current status of trial NCT02953340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 237 participants. The study started on 2017-05-10. Estimated completion is 2019-05-06.
What interventions are being tested in trial NCT02953340?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Pegfilgrastim (DRUG), SPI-2012 (DRUG).
Who is sponsoring clinical trial NCT02953340?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.